PortfoliosLab logoPortfoliosLab logo
RMD vs. INCY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RMD vs. INCY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ResMed Inc. (RMD) and Incyte Corporation (INCY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RMD achieves a -18.71% return, which is significantly lower than INCY's 9.88% return. Over the past 10 years, RMD has outperformed INCY with an annualized return of 13.85%, while INCY has yielded a comparatively lower 3.13% annualized return.


RMD

1D
1.24%
1M
-3.46%
YTD
-18.71%
6M
-22.38%
1Y
-22.01%
3Y*
-2.26%
5Y*
-1.41%
10Y*
13.85%

INCY

1D
0.65%
1M
9.83%
YTD
9.88%
6M
13.75%
1Y
56.79%
3Y*
20.55%
5Y*
5.62%
10Y*
3.13%
*Multi-year figures are annualized to reflect compound growth (CAGR)

RMD vs. INCY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
RMD
ResMed Inc.
-18.71%6.26%34.18%-16.55%-19.47%23.41%38.33%37.85%36.38%39.06%
INCY
Incyte Corporation
9.88%43.00%10.00%-21.83%9.43%-15.61%-0.39%37.32%-32.86%-5.55%

Correlation

The correlation between RMD and INCY is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.30

Correlation (3Y)
Calculated over the trailing 3-year period

0.27

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.31

Correlation (All Time)
Calculated using the full available price history since Jun 2, 1995

0.26

Fundamentals

EPS

RMD:

$13.78

INCY:

$7.06

PE Ratio

RMD:

14.14

INCY:

15.38

PEG Ratio

RMD:

0.44

INCY:

0.02

PS Ratio

RMD:

3.88

INCY:

4.11

Total Revenue (TTM)

RMD:

$5.54B

INCY:

$5.36B

Gross Profit (TTM)

RMD:

$3.42B

INCY:

$3.76B

EBITDA (TTM)

RMD:

$2.10B

INCY:

$1.80B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RMD vs. INCY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RMD
RMD Risk / Return Rank: 1212
Overall Rank
RMD Sharpe Ratio Rank: 77
Sharpe Ratio Rank
RMD Sortino Ratio Rank: 1010
Sortino Ratio Rank
RMD Omega Ratio Rank: 1111
Omega Ratio Rank
RMD Calmar Ratio Rank: 2222
Calmar Ratio Rank
RMD Martin Ratio Rank: 1111
Martin Ratio Rank

INCY
INCY Risk / Return Rank: 8484
Overall Rank
INCY Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
INCY Sortino Ratio Rank: 8484
Sortino Ratio Rank
INCY Omega Ratio Rank: 8282
Omega Ratio Rank
INCY Calmar Ratio Rank: 8585
Calmar Ratio Rank
INCY Martin Ratio Rank: 8282
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RMD vs. INCY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ResMed Inc. (RMD) and Incyte Corporation (INCY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RMDINCYDifference
Sharpe ratioReturn per unit of total volatility

-2.64

Sortino ratioReturn per unit of downside risk

-3.69

Omega ratioGain probability vs. loss probability

0.86

1.31

-0.45

Calmar ratioReturn relative to maximum drawdown

-0.59

3.11

-3.71

Martin ratioReturn relative to average drawdown

-1.34

6.94

-8.28

RMD vs. INCY - Sharpe Ratio Comparison

The current RMD Sharpe Ratio is -0.92, which is lower than the INCY Sharpe Ratio of 1.72. The chart below compares the historical Sharpe Ratios of RMD and INCY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RMD vs. INCY - Drawdown Comparison

The maximum RMD drawdown since its inception was -61.61%, smaller than the maximum INCY drawdown of -98.54%. Use the drawdown chart below to compare losses from any high point for RMD and INCY.


Loading charts...

Drawdown Indicators


RMDINCYDifference

Max Drawdown

Largest peak-to-trough decline

-61.61%

-98.54%

+36.93%

Max Drawdown (1Y)

Largest decline over 1 year

-37.28%

-18.33%

-18.95%

Max Drawdown (3Y)

Largest decline over 3 years

-40.09%

-33.83%

-6.26%

Max Drawdown (5Y)

Largest decline over 5 years

-53.99%

-41.06%

-12.93%

Max Drawdown (10Y)

Largest decline over 10 years

-53.99%

-66.47%

+12.48%

Current Drawdown

Current decline from peak

-33.18%

-28.91%

-4.27%

Average Drawdown

Average peak-to-trough decline

-16.00%

-59.88%

+43.88%

Ulcer Index

Depth and duration of drawdowns from previous peaks

16.49%

8.21%

+8.28%

Volatility

RMD vs. INCY - Volatility Comparison

ResMed Inc. (RMD) and Incyte Corporation (INCY) have volatilities of 9.81% and 9.64%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RMDINCYDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.81%

9.64%

+0.17%

Volatility (6M)

Calculated over the trailing 6-month period

19.30%

22.73%

-3.43%

Volatility (1Y)

Calculated over the trailing 1-year period

24.09%

33.10%

-9.01%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

31.07%

29.32%

+1.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

31.54%

34.29%

-2.75%

Dividends

RMD vs. INCY - Dividend Comparison

RMD's dividend yield for the trailing twelve months is around 1.23%, while INCY has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
INCY
Incyte Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
RMD
ResMed Inc.
1.23%0.94%0.88%1.07%0.83%0.62%0.73%0.98%1.26%1.61%2.03%2.16%

Financials

RMD vs. INCY - Financials Comparison

This section allows you to compare key financial metrics between ResMed Inc. and Incyte Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


600.00M800.00M1.00B1.20B1.40B1.60B20222023202420252026
1.43B
1.27B
(RMD) Total Revenue
(INCY) Total Revenue
Values in USD except per share items

RMD vs. INCY - Profitability Comparison

The chart below illustrates the profitability comparison between ResMed Inc. and Incyte Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%20222023202420252026
62.3%
0
Portfolio components
RMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported a gross profit of 890.98M and revenue of 1.43B. Therefore, the gross margin over that period was 62.3%.

INCY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported a gross profit of 0.00 and revenue of 1.27B. Therefore, the gross margin over that period was 0.0%.

RMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported an operating income of 499.81M and revenue of 1.43B, resulting in an operating margin of 34.9%.

INCY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported an operating income of 301.12M and revenue of 1.27B, resulting in an operating margin of 23.7%.

RMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported a net income of 398.73M and revenue of 1.43B, resulting in a net margin of 27.9%.

INCY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported a net income of 303.33M and revenue of 1.27B, resulting in a net margin of 23.8%.


Frequently Asked Questions


RMD and INCY have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RMD has higher volatility (9.81%) compared to INCY (9.64%). In terms of maximum drawdown, RMD dropped -61.61% vs INCY's -98.54%.

INCY currently has the higher Sharpe Ratio (1.72 vs -0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RMD and INCY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer